Inventor
KOCER BUELENT
DE17 patents
⚠️ This page may combine multiple inventors who share the name “KOCER BUELENT”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
HOFFMANN LA ROCHE
16 patentsUS9447086B2Sep 20, 2016
6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
HOFFMANN LA ROCHE34 citations93
US12209091B2Jan 28, 2025
Isoindolinone derivatives as selective allosteric inhibitors of Egfr mutant cancers
HOFFMANN LA ROCHE7 citations85
US11420961B2Aug 23, 2022
Heterocyclic compounds
HOFFMANN LA ROCHE6 citations74
US11802133B2Oct 31, 2023
Heterocyclic compounds as monoacylglycerol lipase inhibitors
HOFFMANN LA ROCHE2 citations71
US11608347B2Mar 21, 2023
Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitors
HOFFMANN LA ROCHE4 citations71
US11390610B2Jul 19, 2022
Piperazine derivatives as MAGL inhibitors
HOFFMANN LA ROCHE6 citations71
US9758530B2Sep 12, 2017
6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
HOFFMANN LA ROCHE3 citations71
US9266904B2Feb 23, 2016
6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
HOFFMANN LA ROCHE5 citations71
US8940741B2Jan 27, 2015
Inhibitors of bruton's tyrosine kinase
HOFFMANN LA ROCHE4 citations71
US12281124B2Apr 22, 2025
Heterocyclic compounds as monoacylglycerol lipase inhibitors
HOFFMANN LA ROCHE0 citations60
US9693997B2Jul 4, 2017
Antiviral compounds
HOFFMANN LA ROCHE1 citations51
US10435407B2Oct 8, 2019
Triaza-spirodecanones as DDR1 inhibitors
HOFFMANN LA ROCHE0 citations50
US10239876B2Mar 26, 2019
Triaza-spirodecanones as DDR1 inhibitors
HOFFMANN LA ROCHE0 citations50
US12565497B2Mar 3, 2026
Sulfone derivatives
HOFFMANN LA ROCHE0 citations45
US10618897B2Apr 14, 2020
Spiroindolinones as DDR1 inhibitors
HOFFMANN LA ROCHE0 citations41
US9540345B2Jan 10, 2017
Antiviral compounds
HOFFMANN LA ROCHE0 citations38